SINGULAIR (R) as Complementary Therapy to Fixed Association Regimen (0476-363) (STAR)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to assess the treatment effect of montelukast 10mg on the primary endpoint of Asthma Control Questionnaire(ACQ), over a 8-week period, in persistent asthma patients with or without allergic rhinitis.
Condition or disease
Drug: MK0476, montelukast sodium / Duration of Treatment: 8 Weeks
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
15 Years to 80 Years (Child, Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patient is currently a nonsmoker and has been a nonsmoker for at least 1 year
Patient with clinical evidence of mild/moderate asthma with or without allergic rhinitis
Patient has been treated in an emergency room for asthma within 4 weeks or has been hospitalized for asthma within 3 months prior to visit 1
Patient with severe asthma, upper respiratory infection, sinusitis, infectious rhinitis, non-allergic rhinitis
Patient has any active, acute, or chronic pulmonary disorder that is documented by history, physical examination